

Hedy L Kindler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5005545/publications.pdf>

Version: 2024-02-01

35
papers

1,782
citations

361413

20
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

2740
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1343-1373.	1.6	324
2	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2112-2119.	1.1	172
3	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2089-2099.	1.1	139
4	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	7.1	108
5	Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2874-2884.	7.0	103
6	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	1.1	85
7	Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5787-5798.	7.0	72
8	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 697-702.	6.4	70
9	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66
10	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2014, 9, e99816.	2.5	65
11	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3598-3607.	1.6	60
12	Marine ω -3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 438-445.	2.5	52
13	MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma. <i>PLoS ONE</i> , 2014, 9, e105919.	2.5	52
14	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018, 36, 1112-1120.	1.6	50
15	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	1.1	44
16	Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. <i>Lung Cancer</i> , 2004, 45, S125-S127.	2.0	34
17	Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. <i>Scientific Reports</i> , 2016, 6, 24578.	3.3	32
18	A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. , 2013, 1, 8.		30

#	ARTICLE	IF	CITATIONS
19	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	28
20	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) <i>TJ ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	8.3	27
21	A <i>UGT1A1</i> genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. <i>Cancer</i> , 2019, 125, 1629-1636.	4.1	27
22	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	10.7	25
23	Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1642-1647.	1.4	21
24	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
25	Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. <i>British Journal of Cancer</i> , 2021, 124, 564-566.	6.4	18
26	Considering the role of radiation therapy for gastrointestinal stromal tumor. <i>OncoTargets and Therapy</i> , 2014, 7, 713.	2.0	16
27	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2018, 2, pky017.	2.9	10
28	Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <i>UGT1A1</i> Genotype-Guided Dosing. <i>Clinical Cancer Research</i> , 2020, 26, 18-24.	7.0	10
29	9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. <i>Investigational New Drugs</i> , 2004, 22, 323-327.	2.6	6
30	Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). <i>Oncologist</i> , 2022, 27, e494-e505.	3.7	5
31	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab034.	2.9	4
32	The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. <i>Abdominal Radiology</i> , 2022, 47, 1725-1740.	2.1	4
33	Systemic Therapy for Mesothelioma: Turning the Corner. <i>JCO Oncology Practice</i> , 2021, , OP2100785.	2.9	2
34	Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer. <i>American Journal of Cancer</i> , 2005, 4, 185-191.	0.4	1
35	Reply to D. de Fonseca et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2746-2747.	1.6	0